GI Partners has Acquired Clinical Ink

August 14, 2020

GI Partners, a leading private equity investment firm, has announced the acquisition of Clinical Ink (the “Company”), a global clinical trial technology company. Existing investor NovaQuest will continue as a minority investor in the Company.

Cain Brothers was selected as the lead financial advisor to GI Partners given Cain Brothers’ deep domain expertise and strong relationships in the Pharma Services and Healthcare IT sectors.

Headquartered in San Francisco, CA, GI Partners is a private investment firm that has raised over $21 billion in capital from leading institutions around the world to invest in private equity, real estate, and data infrastructure strategies. The firm’s private equity arm invests in the Healthcare, IT Infrastructure, Services and Software sectors with a focus on North American middle market companies.

Clinical Ink, a global clinical technology company, offers data certainty from source to submission. The Company’s Lumenis™ eSource clinical technology and configurable direct data capture, eCOA, ePRO, and eConsent modules enhance the clinical trial workflow by reducing manual labor, providing anytime, anywhere data access, and saving resources. Clinical Ink’s technology has been deployed throughout 60 countries in 70 languages across 300 studies, in all trial phases (I-IV), and over 50 Bring Your Own Device studies.

For more information, please contact:

John Kerins

Managing Director
(212) 981-6891
jkerins@cainbrothers.com

Jill Frew

Managing Director
(212) 981-6916
jfrew@cainbrothers.com